Anthony O’Donoghue, Ph.D. is an Associate Specialist in the Dept. of Pharmaceutical Chemistry at the
University of California, San Francisco. He obtained his Ph.D from the National University of Ireland and
pursued his post-doctoral studies at UC San Francisco in the laboratory of Prof. Charles Craik. At UCSF
he developed a platform technology known as Multiplex Substrate Profiling by Mass Spectrometry (MSPMS) to assess the global proteolytic activity associated with complex biological samples. He has used this
assay to uncover new peptidase targets in infectious organisms and cancer cells. He subsequently joined
the Dept. of Pharmaceutical Chemistry at UCSF as an Associate Specialist and has expanded the
application of MSP-MS to stratify patients based of the proteolytic activity in pancreatic cyst fluid. In
addition, Anthony has characterized the global secreted proteolytic activity from the human pathogens
Schistosoma mansoni, Candida albicans and Cryptococcus neoformans and the bat pathogen
Pseudogymnoascus destructans. Anthony is the co-founder of Alaunus Biosciences, Inc and has worked
as a consultant for Allopartis Biotechnologies (now Novozymes). He was chosen for the 2013 Bioanalysis
Young Investigator Award and was an invited speaker at the Rising Stars Symposium in Chemical
Biology at the University of Utah.